August 25, 2009JAMA1,516 citationsOpen Access
Association of Cytochrome P450 2C19 Genotype With the Antiplatelet Effect and Clinical Efficacy of Clopidogrel Therapy
View Full Paper
Structured PICO
Does the CYP2C19*2 genotype affect the antiplatelet effect and clinical efficacy of clopidogrel therapy?
P
Population
Patients receiving clopidogrel therapy
I
Intervention
CYP2C19*2 genotype
O
Outcome
Platelet response and cardiovascular outcomes
The CYP2C19*2 genotype is associated with reduced antiplatelet efficacy of clopidogrel and worse cardiovascular outcomes.
Abstract
CYP2C19*2 genotype was associated with diminished platelet response to clopidogrel treatment and poorer cardiovascular outcomes.
Cite This Study
Alan R. Shuldiner (2009) studied this question.